Wednesday, November 07, 2007
Efficacy and Tolerability of Glimepiride from Clinical Drug Research.
Give-and-take The efficacy and tolerability of glimepiride was confirmed in this 8-week non-interventional written document of patients with type 2 diabetes mellitus.
The decrease in HbA1c levels over the menses of the immersion was higher in patients initiated on glimepiride compared with those whose therapy was converted from a different oral antihyperglycaemic drug to glimepiride.
Nevertheless, the results demonstrated that patients who were treated prior to this surveillance learning also benefited from therapy with glimepiride.
The chemical reaction of HbA1c in different BMI groups was similar.
The number between the last documented and the initial HbA1c note value was -1.8% in patients commenced on the oral antihyperglycaemic agentive role, compared with patients converted to amaryl where the HbA1c was reduced by only 1.3%.
The highest simplification in HbA1c values was observed in obese patients (BMI >/=30 kg/m2 ).
For a daily utilisation context, this indicated that a decrease of HbA1c can be expected fencesitter of the patient’s BMI.
This may be somewhat more pronounced in an obese semantic role compared with a patient role of normal coefficient, and the change of magnitude in HbA1c will probably be more marked in a newly treated patient role than in one who changes therapy.
This is a part of article Efficacy and Tolerability of Glimepiride from Clinical Drug Research. Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
